Stanton J. Rowe on Entrepreneurship

Featuring Stanton J. Rowe
Corporate Vice President, Advanced Technologies Group
Edwards Lifesciences

Corporation

Location: McDonnell Douglas Engineering Auditorium
Free and open to the public

The Northrop Grumman Entrepreneurship Course for Scientists and Engineers provides a real-world introduction to the theory and practice of entrepreneurship.  Through a series of presentations by prestigious entrepreneurs and industry leaders, participants will explore the various organizational, strategic and financial challenges facing successful and unsuccessful entrepreneurs.  Topics include start-up strategies, business idea evaluation, business plan writing, and introduction to venture capital.

About the Speaker:
Stanton Rowe is responsible for all early stage development work within Edwards Lifesciences Corporation, as well as Discovery, the efforts to identify external technologies or companies which add value to Edwards. These include efforts to development a range of minimally invasive and percutaneous approaches to heart valve replacement or repair. He previously served as President and CEO of Percutaneous Valve Technologies Inc., which was acquired by Edwards in January 2004. 

Prior to PVT, which he helped to found in 1999, Rowe was corporate vice president of business development and strategic planning for Datascope Corp. Prior to this, he was vice president of business development for Johnson & Johnson’s Interventional Systems Division (JJIS), and responsible for the company’s coronary stent development efforts.  

At JJIS, and the related Cordis Corporation, Rowe held a variety of positions with increasing levels of responsibility, including heading the company’s business development, advanced technology, worldwide clinical research, and marketing groups. Rowe joined Cordis after having held several positions in product management for various medical device companies.  He holds a bachelor’s degree from the University of Alabama.  He also sits on the board of directors of both Remon Medical Ltd. and Biomerix Corp.